AR124614A1 - IMMUNO-STIMULANT OLIGONUCLEOTIDES - Google Patents
IMMUNO-STIMULANT OLIGONUCLEOTIDESInfo
- Publication number
- AR124614A1 AR124614A1 ARP180103671A ARP180103671A AR124614A1 AR 124614 A1 AR124614 A1 AR 124614A1 AR P180103671 A ARP180103671 A AR P180103671A AR P180103671 A ARP180103671 A AR P180103671A AR 124614 A1 AR124614 A1 AR 124614A1
- Authority
- AR
- Argentina
- Prior art keywords
- oligonucleotides
- oligonucleotide
- immunostimulatory
- guanine
- nucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 9
- 230000003308 immunostimulating effect Effects 0.000 title abstract 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 5
- 229960001438 immunostimulant agent Drugs 0.000 title 1
- 239000003022 immunostimulating agent Substances 0.000 title 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 5
- 102000002689 Toll-like receptor Human genes 0.000 abstract 1
- 108020000411 Toll-like receptor Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se describen oligonucleótidos inmunoestimulantes y composiciones y métodos de uso de estos. Más específicamente, se describen oligonucleótidos inmunoestimulantes, métodos para optimizar las propiedades inmunoestimulantes de los oligonucleótidos, y métodos para usar los oligonucleótidos inmunoestimulantes para provocar una respuesta inmunitaria mediada por el receptor tipo toll 21 (TLR21). Reivindicación 1: Un oligonucleótido inmunoestimulante que comprende al menos un motivo CpG y una secuencia enriquecida con nucleótido de guanina que comienza en o a los cuatro nucleótidos del extremo 5 del oligonucleótido. Reivindicación 2: El oligonucleótido de la reivindicación 1, donde la secuencia enriquecida con nucleótido de guanina comprende una primera pluralidad de nucleótidos de guanina. Reivindicación 7: El oligonucleótido de cualquiera de las reivindicaciones antecedentes que comprende además una segunda pluralidad de nucleótidos de guanina entre la primera pluralidad de nucleótidos de guanina y el al menos un motivo CpG.Immunostimulatory oligonucleotides and compositions and methods of use thereof are described herein. More specifically, immunostimulatory oligonucleotides, methods of optimizing the immunostimulatory properties of the oligonucleotides, and methods of using the immunostimulatory oligonucleotides to elicit a toll-like receptor 21 (TLR21)-mediated immune response are described. Claim 1: An immunostimulatory oligonucleotide comprising at least one CpG motif and a guanine nucleotide-enriched sequence beginning at or at the 5-terminal four nucleotides of the oligonucleotide. Claim 2: The oligonucleotide of claim 1, wherein the guanine nucleotide-enriched sequence comprises a first plurality of guanine nucleotides. Claim 7: The oligonucleotide of any of the preceding claims further comprising a second plurality of guanine nucleotides between the first plurality of guanine nucleotides and the at least one CpG motif.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17207750 | 2017-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124614A1 true AR124614A1 (en) | 2023-04-19 |
Family
ID=60673709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103671A AR124614A1 (en) | 2017-12-15 | 2018-12-14 | IMMUNO-STIMULANT OLIGONUCLEOTIDES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR124614A1 (en) |
-
2018
- 2018-12-14 AR ARP180103671A patent/AR124614A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000113A (en) | IMMUNOSTIMULATING OLIGONUCLEOTIDES | |
| SV2018005619A (en) | COMPOSITIONS OF OLIGONUCLEOTIDOS AND METHODS OF THE SAME | |
| MX2020004600A (en) | Oligonucleotide constructs and uses thereof. | |
| MX2020007259A (en) | BISULPHITE-FREE IDENTIFICATION OF CYTOSINE MODIFICATIONS BY BASE RESOLUTION. | |
| CR8423A (en) | CLASS C NUCLEOTID ANALOGS WITH IMPROVED IMMUNO-STIMULATING POWER | |
| MX2019012295A (en) | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use. | |
| CL2016000650A1 (en) | Vaccine composition comprising an antigen and an adjuvant formulation, comprising at least 50% v / v of an oil phase, monophosphoryl lipid a (mpl-a) or an analog thereof and an immunostimulate oligonucleotide; and use of the vaccine composition to prepare a medicament. | |
| CR20190294A (en) | COMPOSITIONS OF SERPINE1 RNAi AND ITS METHODS OF USE | |
| CO6382137A2 (en) | IMMUNO-STIMULATING OLIGONUCLEOTIDES | |
| MX374553B (en) | NUCLEIC ACID DERIVATIVE THAT HAS IMMUNOSTIMILATORY ACTIVITY. | |
| DOP2016000223A (en) | IMMUNOSTIMULATING PLASMIDS | |
| MX2020009150A (en) | Cpg amphiphiles and uses thereof. | |
| MX2017009306A (en) | VACCINE AGAINST FEVERY FEVER. | |
| MX2018001126A (en) | Therapeutic oligonucleotides. | |
| CL2020002038A1 (en) | Oligonucleotides to modulate the expression of tmem106b. | |
| PH12019502063A1 (en) | Nucleic acid derivative having immunostimulatory activity | |
| AR124614A1 (en) | IMMUNO-STIMULANT OLIGONUCLEOTIDES | |
| AR097029A1 (en) | ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE | |
| AR113949A1 (en) | IMMUNOSTIMULATING OLIGONUCLEOTIDES | |
| AR105488A1 (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND METHODS OF THE SAME | |
| TH2001003350A (en) | Immune-stimulating oligonucleotides | |
| CL2016001052A1 (en) | Molecular markers, method, oligonucleotides and genotyping kit for individuals of the genus nothofagus | |
| AR105127A1 (en) | INACTIVATED VACCINES AGAINST CANINE INFLUENZA, METHODS TO PREPARE THEM AND THEIR USES | |
| AR093687A2 (en) | VACCINES | |
| CR7694A (en) | IMMUNE STIMULATING NUCLEIC ACIDS |